Kellye Kirkbride

Kellye Kirkbride has over 20 years of experience in the biotechnology and research industry. Kellye began their career in 2000 as an Undergraduate Research in Biology at Indiana University Bloomington. In 2001, they began their PhD studies at Duke University, where they performed biochemical and cancer research understanding ligand and receptor interactions. In 2008, they became a Biology Instructor at Alamance Community College and a Postdoctoral Research Fellow at Vanderbilt University Medical Center, where they gained extensive experience and skills in cancer and cell biology techniques and approaches. In 2013, they became a Postdoctoral Research Scholar at Vanderbilt University, where they were responsible for determining the in vivo efficacy of nanocarriers for drug delivery to tumors. From 2015 to 2017, they were a Senior Biological Scientist at StemSynergy Therapeutics, Inc., where they were a member of a biopharmaceutical company focused on the discovery of small-molecule drugs that target WNT and Sonic Hedgehog (SHH) signaling, pathways fundamental to cancer and tissue regeneration. From 2017 to 2020, they were a Scientist III and Scientist II at Pierian Biosciences, where they were co-team leader for the development and design of the ChemoINTEL platform, an automated, multiplexed, high-content image-based human cancer in vitro diagnostic. Kellye was also responsible for study plan design and execution, including data analysis, interpretation and summation. In 2020, they became Quality Assurance Manager and Quality System Specialist at iRepertoire, Inc.

Kellye Kirkbride holds a PhD in Molecular Cancer Biology from Duke University and a B.S. in Biology from Indiana University Bloomington.